Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Pembrolizumab|RADIATION: Radiation Therapy|DRUG: Axatilimab
Sponsor: Stephen Shiao
Collaborators: Merck Sharp & Dohme LLC|Incyte Corporation